Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 11, 2011, Pages 1177-1183

  Ceccato, M G B ^a   Bonolo, P F ^b   Souza Neto, A I ^c   Araujo F S ^c   Freitas, M I F ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c UNIVERSIDADE JOSÉ DO ROSÁRIO VELLANO   (Brazil)

Author keywords

Antiretroviral therapy; Dyslipidemia; Lipodystrophy; Management

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTICLE; BRAZIL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DYSLIPIDEMIA; EDUCATIONAL STATUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; SENESCENCE; SEX DIFFERENCE; TREATMENT DURATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80455144753     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500129     Document Type: Article

References (32)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
2. Troll JG. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep 2011; 13: 51-56.
3. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004; 170: 229-238.
4. Fichtenbaum CJ. Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons. HIV Clin Trials 2004; 5: 416-433.
5. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
6. Villarroya F, Domingo P, Giralt M. Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim Biophys Acta 2010; 1801: 392-399.
7. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23: 625-630.
8. Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005; 39: 199-202.
9. van Vonderen MG, Gras L, Wit F, Brinkman K, van der Ende ME, Hoepelman AI, et al. Baseline lipid levels rather than the presence of reported body shape changes determine the degree of improvement in lipid levels after switching to atazanavir. HIV Clin Trials 2009; 10: 168-180.
10. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIVinfected adults: a case-control study. Lancet 2003; 361: 726-735.
11. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-1316.
12. Raimundo P, Miranda A, Ribeiro J, Mansinho K. [Cardiovascular risk in HIV infected patients]. Acta Med Port 2010; 23: 669-676.
13. Tomazic J, Silic A, Karner P, Vidmar L, Maticic M, Poljak M, et al. Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients. Wien Klin Wochenschr 2004; 116: 755-759.
14. Jevtovic DJ, Dragovic G, Salemovic D, Ranin J, Djurkovic-Djakovic O. The metabolic syndrome, an epidemic among HIV-infected patients on HAART. Biomed Pharmacother 2009; 63: 337-342.
15. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-1052.
16. Kramer AS, Lazzarotto AR, Sprinz E, Manfroi WC. Metabolic abnormalities, antiretroviral therapy and cardiovascular disease in elderly patients with HIV. Arq Bras Cardiol 2009; 93: 561-568.
17. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
18. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17 (Suppl 1): S141-S148.
19. Tsiodras S, Poulia KA, Yannakoulia M, Chimienti SN, Wadhwa S, Karchmer AW, et al. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism 2009; 58: 854-859.
20. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
21. Ronchini KR, Duarte AJ, Casseb JS, Gidlund M. Cardiovascular complications and increased levels of circulating modified low density lipoprotein in HIV patients and patients with lipodystrophy. Braz J Med Biol Res 2004; 37: 119-122.
22. Brasil. Ministério da Saúde. Coordenação Nacional de DST and AIDS. Consenso: recomendações para a antiretroviral therapy em adultos and adolescentes infectados pelo HIV, 2008. Available at [http://www.AIDS.gov.br]. Accessed November 18, 2009.
23. Sposito AC, Caramelli B, Fonseca FA, Bertolami MC, Afiune NA, Souza AD, et al. [IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology]. Arq Bras Cardiol 2007; 88 (Suppl 1): 2-19.
24. Centers for Disease and Prevention. Revised classification system for HIV infection and expanded surveillance case definitions for AIDS among adolescents and adults. 1993. Available at [http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm]. Accessed September 22, 2006.
25. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
26. de Araújo PS, de Alencar X, Lopes CF, Duarte JY, da Silva MM, Carneiro EM. Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia. Rev Inst Med Trop São Paulo 2007; 49: 73-78.
27. Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF. Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 2005; 178: 165-172.
28. Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008; 47: 304-311.
29. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16: 2447-2454.
30. Pérez-Camacho I, Camacho A, Torre-Cisneros J, Rivero A. Factores de riesgo cardiovascular dependientes del tratamiento antirretroviral. Enferm Infecc Microbiol Clin 2009; 27 (Supl 1): 24-32.
31. Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte A, Pradier C, et al. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2009; 32: 474-480.
32. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio MA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-1074.